KR101739923B1 - Ｒ)-3-(4-(2-(2-메틸테트라졸-5-일)피리딘-5-일)-3-플루오로페닐)-5-히드록시메틸 옥사졸리딘-2-온 디히드로겐 포스페이트의 결정형 - Google Patents

Ｒ)-3-(4-(2-(2-메틸테트라졸-5-일)피리딘-5-일)-3-플루오로페닐)-5-히드록시메틸 옥사졸리딘-2-온 디히드로겐 포스페이트의 결정형 Download PDF

Info

Publication number
KR101739923B1
KR101739923B1 KR1020117020614A KR20117020614A KR101739923B1 KR 101739923 B1 KR101739923 B1 KR 101739923B1 KR 1020117020614 A KR1020117020614 A KR 1020117020614A KR 20117020614 A KR20117020614 A KR 20117020614A KR 101739923 B1 KR101739923 B1 KR 101739923B1
Authority
KR
South Korea
Prior art keywords
crystalline form
pharmaceutical composition
delete delete
crystalline
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117020614A
Other languages
English (en)
Korean (ko)
Other versions
KR20110120311A (ko
Inventor
카타리나 라이헨바헤르
로버트 제이. 두굳
재클린 에이. 심슨
더글라스 필립슨
Original Assignee
머크 샤프 앤드 돔 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42289775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101739923(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 머크 샤프 앤드 돔 코포레이션 filed Critical 머크 샤프 앤드 돔 코포레이션
Publication of KR20110120311A publication Critical patent/KR20110120311A/ko
Application granted granted Critical
Publication of KR101739923B1 publication Critical patent/KR101739923B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020117020614A 2009-02-03 2010-02-03 Ｒ)-3-(4-(2-(2-메틸테트라졸-5-일)피리딘-5-일)-3-플루오로페닐)-5-히드록시메틸 옥사졸리딘-2-온 디히드로겐 포스페이트의 결정형 Active KR101739923B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14940209P 2009-02-03 2009-02-03
US61/149,402 2009-02-03
PCT/US2010/023122 WO2010091131A1 (en) 2009-02-03 2010-02-03 Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177008992A Division KR20170040371A (ko) 2009-02-03 2010-02-03 Ｒ)-3-(4-(2-(2-메틸테트라졸-5-일)피리딘-5-일)-3-플루오로페닐)-5-히드록시메틸 옥사졸리딘-2-온 디히드로겐 포스페이트의 결정형

Publications (2)

Publication Number Publication Date
KR20110120311A KR20110120311A (ko) 2011-11-03
KR101739923B1 true KR101739923B1 (ko) 2017-05-25

Family

ID=42289775

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020117020614A Active KR101739923B1 (ko) 2009-02-03 2010-02-03 Ｒ)-3-(4-(2-(2-메틸테트라졸-5-일)피리딘-5-일)-3-플루오로페닐)-5-히드록시메틸 옥사졸리딘-2-온 디히드로겐 포스페이트의 결정형
KR1020177008992A Ceased KR20170040371A (ko) 2009-02-03 2010-02-03 Ｒ)-3-(4-(2-(2-메틸테트라졸-5-일)피리딘-5-일)-3-플루오로페닐)-5-히드록시메틸 옥사졸리딘-2-온 디히드로겐 포스페이트의 결정형
KR1020177034181A Active KR101918678B1 (ko) 2009-02-03 2010-02-03 Ｒ)-3-(4-(2-(2-메틸테트라졸-5-일)피리딘-5-일)-3-플루오로페닐)-5-히드록시메틸 옥사졸리딘-2-온 디히드로겐 포스페이트의 결정형

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020177008992A Ceased KR20170040371A (ko) 2009-02-03 2010-02-03 Ｒ)-3-(4-(2-(2-메틸테트라졸-5-일)피리딘-5-일)-3-플루오로페닐)-5-히드록시메틸 옥사졸리딘-2-온 디히드로겐 포스페이트의 결정형
KR1020177034181A Active KR101918678B1 (ko) 2009-02-03 2010-02-03 Ｒ)-3-(4-(2-(2-메틸테트라졸-5-일)피리딘-5-일)-3-플루오로페닐)-5-히드록시메틸 옥사졸리딘-2-온 디히드로겐 포스페이트의 결정형

Country Status (29)

Country Link
US (6) US8426389B2 (enExample)
EP (1) EP2393808B1 (enExample)
JP (1) JP5584705B2 (enExample)
KR (3) KR101739923B1 (enExample)
CN (2) CN107082790A (enExample)
AP (1) AP2987A (enExample)
AU (1) AU2010210627B2 (enExample)
BR (1) BRPI1008829A2 (enExample)
CA (1) CA2751392C (enExample)
CL (1) CL2011001855A1 (enExample)
CO (1) CO6620071A2 (enExample)
CR (1) CR20110464A (enExample)
CU (1) CU24089B1 (enExample)
DO (1) DOP2011000251A (enExample)
EC (1) ECSP11011285A (enExample)
ES (1) ES2734724T3 (enExample)
IL (1) IL214401B (enExample)
MA (1) MA33092B1 (enExample)
MX (3) MX2011008093A (enExample)
MY (1) MY156354A (enExample)
NZ (3) NZ620458A (enExample)
PE (1) PE20120585A1 (enExample)
PH (1) PH12014500092A1 (enExample)
RU (2) RU2655928C1 (enExample)
SG (2) SG10201500207QA (enExample)
TN (1) TN2011000381A1 (enExample)
UA (1) UA114068C2 (enExample)
WO (1) WO2010091131A1 (enExample)
ZA (2) ZA201106412B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
MX2011003820A (es) * 2008-10-10 2011-06-16 Trius Therapeutics Metodos para preparar oxazolidinonas y composiciones que las contienen.
NZ620458A (en) 2009-02-03 2015-10-30 Merck Sharp & Dohme Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
US8580767B2 (en) * 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use
US8461188B2 (en) 2011-10-20 2013-06-11 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
WO2015054246A1 (en) * 2013-10-07 2015-04-16 Trius Therapeutics, Inc. Methods of treating subjects with renal impairment using tedizolid
WO2015158202A1 (zh) * 2014-04-18 2015-10-22 杭州普晒医药科技有限公司 一种噁唑烷酮类抗生素的晶型及制备方法、组合物和用途
WO2016009401A2 (en) * 2014-07-18 2016-01-21 Dr. Reddy's Laboratories Limited Preparation of tedizolid phosphate
CN104327119A (zh) * 2014-10-17 2015-02-04 苏州明锐医药科技有限公司 磷酸泰地唑胺的制备方法
WO2016063246A1 (en) * 2014-10-22 2016-04-28 Sun Pharmaceutical Industries Limited Crystalline form r of tedizolid phosphate
WO2016088101A1 (en) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Processes for the preparation of tedizolid phosphate and its intermediates
WO2016088102A1 (en) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Processes for the preparation of tedizolid phosphate and its intermediates
WO2016088100A1 (en) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Processes for the preparation of tedizolid phosphate and its intermediates
CZ306245B6 (cs) * 2014-12-11 2016-10-26 Univerzita Karlova v Praze Farmaceutická fakulta v Hradci Králové Substituovaný fenyltetrazol, jeho použití a farmaceutický přípravek ho obsahující
CN104558034A (zh) * 2015-01-21 2015-04-29 齐鲁制药有限公司 磷酸特地唑胺二钠盐的新晶型及其制备方法
CN105837634B (zh) * 2015-01-30 2020-09-04 上海创诺制药有限公司 一种泰地唑胺磷酸酯结晶体及其制备方法
CN104592218B (zh) * 2015-02-13 2015-11-04 江苏欧信医药化工有限公司 一种泰地唑胺的合成方法
CN106146485B (zh) * 2015-04-01 2021-04-30 上海迪赛诺化学制药有限公司 一种制备泰地唑胺的方法及其得到的泰地唑胺结晶体
CN106146558A (zh) * 2015-04-10 2016-11-23 博瑞生物医药（苏州）股份有限公司 新的噁唑烷酮类化合物及其制备方法
CN106317114B (zh) * 2015-07-02 2018-11-20 南京优科制药有限公司 一种磷酸特地唑胺的制备方法
CN105085570B (zh) * 2015-09-12 2017-11-28 山东罗欣药业集团股份有限公司 一种磷酸特地唑胺化合物及其制备方法
CN105287407B (zh) * 2015-11-24 2018-09-21 南京正大天晴制药有限公司 一种注射用磷酸特地唑胺
CN107121503B (zh) * 2017-03-14 2020-04-28 南京优科制药有限公司 一种磷酸特地唑胺及其有关物质的分析方法
CN108948079A (zh) * 2017-05-17 2018-12-07 上海奥博生物医药技术有限公司 一种特地唑胺二铵盐及晶型与其制备方法
EP3723758A4 (en) * 2017-12-13 2021-06-23 Merck Sharp & Dohme Corp. PHARMACEUTICAL COMPOSITIONS OF TEDICOLIDE PHOSPHATE
KR102777328B1 (ko) 2018-07-25 2025-03-10 자이두스 라이프사이언시즈 리미티드 포유류 감염 치료를 위한 신규 화합물
BR112022025918A2 (pt) 2020-06-18 2023-03-14 Akagera Medicines Inc Compostos de oxazolidinona, composições lipossomais que compreendem compostos de oxazolidinona e métodos de uso dos mesmos
CN112957332B (zh) * 2021-02-04 2023-04-25 海南通用康力制药有限公司 注射用磷酸特地唑胺及其质量标准
CN112957333B (zh) * 2021-02-05 2022-11-22 海南通用康力制药有限公司 注射用磷酸特地唑胺及其制备方法
CN113197874B (zh) * 2021-04-28 2023-05-26 北京福元医药股份有限公司 一种磷酸特地唑胺口服固体制剂

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU80081A1 (fr) 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
US4340606A (en) 1980-10-23 1982-07-20 E. I. Du Pont De Nemours And Company 3-(p-Alkylsulfonylphenyl)oxazolidinone derivatives as antibacterial agents
FR2500450A1 (fr) 1981-02-25 1982-08-27 Delalande Sa Nouveaux derives aminomethyl-5 oxazolidiniques, leur procede de preparation et leur application en therapeutique
US4461773A (en) 1982-09-15 1984-07-24 E. I. Dupont De Nemours And Company P-Oxooxazolidinylbenzene compounds as antibacterial agents
CA1320730C (en) 1987-10-16 1993-07-27 The Du Pont Merck Pharmaceutical Company Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5254577A (en) 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5144911A (en) * 1990-11-28 1992-09-08 Moore Cheri L Component bed system for a pet
CA2119556C (en) 1991-11-01 2004-07-06 Michael Robert Barbachyn Substituted aryl- and heteroaryl-phenyloxazolidinones
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
AU670842B2 (en) 1992-12-08 1996-08-01 Pharmacia & Upjohn Company Tropone-substituted phenyloxazolidinone antibacterial agents
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
WO1995014684A1 (en) 1993-11-22 1995-06-01 The Upjohn Company Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones
GB9702213D0 (en) 1996-02-24 1997-03-26 Zeneca Ltd Chemical compounds
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
MXPA02012045A (es) 2000-06-05 2003-10-15 Dong A Pharm Co Ltd Nuevos derivados de oxazolidinona y proceso para su preparacion.
US20020115669A1 (en) 2000-08-31 2002-08-22 Wiedeman Paul E. Oxazolidinone chemotherapeutic agents
YU52403A (sh) 2000-12-26 2006-03-03 Dr.Reddy's Research Foundation Heterociklična jedinjenja koja imaju antibakterijsko dejstvo, postupak za njihovo dobijanje i farmaceutske smeše koje ih sadrže
JP2004531518A (ja) 2001-04-07 2004-10-14 アストラゼネカ アクチボラグ スルホンイミド基を含有する、抗生物質としてのオキサゾリジノン
US6623140B2 (en) 2001-04-13 2003-09-23 Scott R. Watterson Illumination device having multiple light sources
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
KR20040044886A (ko) 2001-09-11 2004-05-31 아스트라제네카 아베 항균제로서의 옥사졸리디논 및(또는) 이속사졸린
JP2005519870A (ja) 2001-10-25 2005-07-07 アストラゼネカ アクチボラグ 抗菌活性をもつアリール置換オキサゾリジノン類
NZ515881A (en) 2001-12-03 2004-09-24 New Zealand Dairy Board Cheese flavour ingredient and method of its production
AR038536A1 (es) * 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
JP2005531504A (ja) 2002-02-28 2005-10-20 アストラゼネカ アクチボラグ 化学化合物
MXPA04008312A (es) 2002-02-28 2004-11-26 Astrazeneca Ab Derivados de 3-cilil-5-(anillo de 5 miembros que contienen nitrogeno)-metil-oxazolidinona y sus uso como agentes antibacterianos.
JP2006508192A (ja) 2002-11-28 2006-03-09 アストラゼネカ アクチボラグ 抗細菌薬としてのオキサゾリジノンおよび／またはイソオキサゾリン誘導体
US7498350B2 (en) 2002-11-28 2009-03-03 Astrazeneca Ab Oxazolidinones as antibacterial agents
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
TW200500360A (en) 2003-03-01 2005-01-01 Astrazeneca Ab Hydroxymethyl compounds
GB0306358D0 (en) 2003-03-20 2003-04-23 Astrazeneca Ab Chemical compounds
NZ544237A (en) 2003-07-02 2008-09-26 Merck & Co Inc Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof
JP2007521283A (ja) 2003-07-02 2007-08-02 メルク アンド カンパニー インコーポレーテッド シクロプロピル基で置換されたオキサゾリジノン系抗生物質およびその誘導体
NZ529860A (en) 2003-11-28 2006-10-27 Ovita Ltd Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
WO2005051933A1 (en) 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited An improved process for the synthesis of 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylic acid tert-butyl ester, a key intermediate for oxazolidinone antimicrobials and compounds prepared thereby
US7129259B2 (en) 2003-12-17 2006-10-31 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
US20070191336A1 (en) 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
GB0411596D0 (en) 2004-05-25 2004-06-30 Astrazeneca Ab Chemical process
US20080064689A1 (en) 2004-05-25 2008-03-13 Astrazeneca Ab 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents
US20070208062A1 (en) 2004-05-25 2007-09-06 Astrazeneca Ab 3-(4-(2-dihydroisoxazol-3-ylpyridin-5-yl)phenyl)-5-triazol-1-ylmethyloxazolidin-2-one derivatives as mao inhibitors for the treatment of bacterial infections
CA2566963A1 (en) 2004-05-25 2005-12-08 Astrazeneca Ab 3-[4-{6-substituted alkanoyl pyridin-3-yl}-3-phenyl]-5-(1h-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-ones as antibacterial agents
AU2005247670A1 (en) 2004-05-25 2005-12-08 Astrazeneca Ab 3- {4- (pyridin-3-yl) phenyl} -5- (1H-1, 2, 3-triazol-1-ylmethyl) -1, 3-oxazolidin-2-ones as antibacterial agents
US20100286211A1 (en) 2004-10-08 2010-11-11 Biswajit Das Oxazolidinone derivatives as antimicrobials
WO2007023507A2 (en) 2005-06-20 2007-03-01 Wockhardt Limited Oxazolidinones bearing antimicrobial activity composition and methods of preparation
WO2007138381A2 (en) 2005-10-14 2007-12-06 Targanta Therapeutics Inc. Phosphonated oxazolidinones and uses thereof for the prevention and treatment of bone and joint infections
CA2695616C (en) * 2007-08-06 2015-11-24 Micurx Pharmaceuticals, Inc. Antimicrobial ortho-fluorophenyl oxazolidinones for treatment of bacterial infections
CN101220001A (zh) * 2008-01-25 2008-07-16 浙江博泰化工有限公司 一种利奈唑酮的合成方法
MX2011003820A (es) 2008-10-10 2011-06-16 Trius Therapeutics Metodos para preparar oxazolidinonas y composiciones que las contienen.
NZ620458A (en) 2009-02-03 2015-10-30 Merck Sharp & Dohme Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
US8580767B2 (en) 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Antimicrobial Agents and Chemotherapy, 50(9), 3170-3172, 2006

Also Published As

Publication number Publication date
DOP2011000251A (es) 2011-11-15
CL2011001855A1 (es) 2011-11-11
MY156354A (en) 2016-02-15
UA114068C2 (xx) 2017-04-25
US9988406B2 (en) 2018-06-05
KR20110120311A (ko) 2011-11-03
US9624250B2 (en) 2017-04-18
CU24089B1 (es) 2015-04-29
PH12014500092B1 (en) 2014-12-01
CN107082790A (zh) 2017-08-22
US20100227839A1 (en) 2010-09-09
KR101918678B1 (ko) 2018-11-14
ZA201106412B (en) 2013-11-27
BRPI1008829A2 (pt) 2016-03-15
CR20110464A (es) 2016-07-20
AU2010210627B2 (en) 2016-03-03
MX384300B (es) 2025-03-14
NZ620458A (en) 2015-10-30
US20160176905A1 (en) 2016-06-23
MA33092B1 (fr) 2012-03-01
CO6620071A2 (es) 2013-02-15
PE20120585A1 (es) 2012-06-13
US20170275315A1 (en) 2017-09-28
US20180251482A1 (en) 2018-09-06
AP2987A (en) 2014-09-30
KR20170135984A (ko) 2017-12-08
CU20110155A7 (es) 2012-02-15
US20180244704A1 (en) 2018-08-30
EP2393808B1 (en) 2019-05-08
RU2011136537A (ru) 2013-03-10
SG173497A1 (en) 2011-09-29
CN102439006A (zh) 2012-05-02
EP2393808A1 (en) 2011-12-14
ZA201306536B (en) 2014-05-28
NZ594408A (en) 2014-03-28
US10442829B2 (en) 2019-10-15
JP2012516894A (ja) 2012-07-26
PH12014500092A1 (en) 2014-12-01
CA2751392C (en) 2017-03-28
US8426389B2 (en) 2013-04-23
IL214401B (en) 2021-03-25
MX2020011773A (es) 2020-11-24
JP5584705B2 (ja) 2014-09-03
CA2751392A1 (en) 2010-08-12
US20130310343A1 (en) 2013-11-21
KR20170040371A (ko) 2017-04-12
MX2011008093A (es) 2011-11-29
RU2655928C1 (ru) 2018-05-30
AP2011005835A0 (en) 2011-08-31
IL214401A0 (en) 2011-09-27
TN2011000381A1 (en) 2013-03-27
ECSP11011285A (es) 2011-10-31
AU2010210627A1 (en) 2011-08-25
WO2010091131A1 (en) 2010-08-12
NZ712289A (en) 2017-03-31
ES2734724T3 (es) 2019-12-11
US10065947B1 (en) 2018-09-04
SG10201500207QA (en) 2015-03-30

Similar Documents

Publication Publication Date Title
KR101739923B1 (ko) Ｒ)-3-(4-(2-(2-메틸테트라졸-5-일)피리딘-5-일)-3-플루오로페닐)-5-히드록시메틸 옥사졸리딘-2-온 디히드로겐 포스페이트의 결정형
JP2001512712A (ja) ヌクレオチドアナログ組成物
US8580767B2 (en) Oxazolidinone containing dimer compounds, compositions and methods to make and use
US20080076812A1 (en) Formulations of sitaxsentan sodium
HK1237349A1 (en) A crystalline form of oxazolidinone compound
US12286394B2 (en) Crystalline form of treosulfan
US20120010171A1 (en) Nucleotide Analogue Prodrug and the Preparation Thereof
EA043433B1 (ru) Кристаллическая форма треосульфана

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110902

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150202

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20151210

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160512

Patent event code: PE09021S01D

AMND Amendment
E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20160901

Patent event code: PE09021S02D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170302

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160901

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20160512

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170331

PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170302

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20161201

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20160708

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20150202

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20170412

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20170331

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20170302

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20161201

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20160708

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20150202

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20170519

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20170522

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20200324

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20210329

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20220325

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20230327

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20240320

Start annual number: 8

End annual number: 8